Noninvasive biomarkers would be valuable for diagnosis and monitoring of eosinophilic esophagitis (EoE). The aim of this study was to determine the utility of a panel of serum biomarkers for the diagnosis and management of EoE.
INTRODUCTION
Th e current diagnostic algorithm for eosinophilic esophagitis (EoE) requires upper endoscopy and biopsy, an invasive procedure, to assess for esophageal eosinophilia in patients with symptoms of esophageal dysfunction (1) (2) (3) . In practice, several procedures are needed: the index endoscopy where the diagnosis is suspected, the follow-up endoscopy to confi rm the diagnosis aft er a proton pump inhibitor (PPI) trial, and a third endoscopy to assess tissue response to therapy ( 1, 4 ) . Th is approach is suboptimal because of high costs associated with the multiple procedures ( 5 ) , as well as the possibility of procedural complications. Noninvasive biomarkers hold the potential to decrease costs and increase safety, but none has been clinically validated for routine use in EoE (6) (7) (8) .
Utility of a Noninvasive Serum Biomarker Panel for Diagnosis and Monitoring of Eosinophilic Esophagitis: A Prospective Study
Candidate biomarkers could be selected from the pathogenesis of EoE, which is currently thought to involve a Th 2-mediated response to allergens (9) (10) (11) (12) . A number of cytokines, including interleukin (IL)-4, IL-5, and IL-13 (13) (14) (15) (16) (17) (18) , chemokines, such as eotaxin-3, which is the most highly upregulated gene in EoE ( 15, (19) (20) (21) , and markers of eosinophil activation, such as granule proteins ( 18, (22) (23) (24) , have all been shown to be elevated in EoE as compared with controls. However, these fi ndings have been generally reported in the esophageal tissue, and data are primarily related to pathogenic studies in EoE ( 15, (19) (20) (21) (25) (26) (27) (28) (29) . Th e true clinical utility of Th 2-related cytokines, chemokines, and eosinophil granules as noninvasive serum biomarkers has yet to be demonstrated for either diagnosis or monitoring of treatment for EoE. Given the high cost of diagnosis and management of EoE using endoscopy fi ndings, the translation of the research fi ndings above into a viable serum test for the presence and/or severity of EoE would be of enormous value.
Th e aim of this study was to determine whether a panel of serum biomarkers based on the known pathogenesis of EoE could distinguish EoE from controls at baseline for diagnosis of EoE. We additionally sought to determine whether these biomarkers might have utility for monitoring EoE aft er treatment. We hypothesized that subjects with EoE would have signifi cantly higher serum levels of one or more of these biomarkers, compared with clinically relevant non-EoE controls, and that these levels might decrease among the EoE cases aft er eff ective steroid therapy.
METHODS

Study design, patients, clinical data, and follow-up
We conducted a prospective cohort study at the University of North Carolina (UNC) from July 2011 to December 2013. Consecutive adult patients (age 18-80 years) undergoing routine outpatient esophagogastroduodenoscopy were approached if they had upper gastrointestinal symptoms suggestive of esophageal dysfunction (e.g., dysphagia, food impaction, heartburn, refl ux, chest pain). Subjects provided informed consent, including consent for the future use of stored specimens, and were enrolled before the endoscopy. Subjects were excluded if they had a known (prevalent) diagnosis of EoE or a diff erent eosinophilic gastrointestinal disorder, gastrointestinal bleeding, active anticoagulation, known esophageal cancer, prior esophageal surgery, known esophageal varices, medical instability or multiple comorbidities precluding enrollment in the clinical opinion of the endoscopist, or an inability to read or understand the consent form. Th is study was approved by the UNC Institutional Review Board and registered on clinicaltrials.gov (NCT 01988285).
Cases were diagnosed with EoE if they met consensus guidelines (1) (2) (3) . Specifi cally, they were required to have at least one typical symptom of esophageal dysfunction; at least 15 eosinophils per high-power fi eld (eos/h.p.f.) on esophageal biopsy persisting aft er an 8-week PPI trial (20-40 mg twice daily of any of the available agents, prescribed at the discretion of the clinician); and other causes of esophageal eosinophilia excluded. Of note, baseline data for the EoE cases were obtained aft er the PPI trial, at the time of the confi rmatory esophagogastroduodenoscopy, but before receiving the histologic results confi rming the diagnosis or provision of EoE-specifi c treatment, so as to minimize potential recall bias. Controls were subjects who, aft er endoscopy and biopsy, did not meet the clinical or histologic criteria for EoE. Subjects with PPI-responsive esophageal eosinophilia were not included in this study.
Clinical data were collected using a standardized case report form. Items recorded included demographics, symptoms, concomitant atopic diseases, indications for endoscopy, and endoscopic fi ndings. Food allergy datawere collected by patient self-report on a prospectively administered questionnaire and could therefore include both food allergies and sensitizations. Systematic allergy testing was not a component of this study. During endoscopy, research-protocol esophageal biopsies were obtained (two from the proximal, one from the mid, and two from the distal esophagus) to maximize EoE diagnostic sensitivity ( 30, 31 ) . Gastric and duodenal biopsies were also collected for research purposes to exclude concomitant eosinophilic gastroenteritis. Additional clinical biopsies were taken as indicated at the discretion of the endoscopist. Esophageal eosinophil counts were quantifi ed by the study pathologists using our previously validated methods ( 32 ) . In brief, slides were masked to case/control status, digitized, and reviewed with Aperio ImageScope (Aperio Technologies, Vista, CA). Five microscopy fi elds from each of the fi ve biopsies were examined to determine the maximum eosinophil density (eosinophils/mm 2 [eos/mm 2 ]). So, results could be compared with prior studies, eosinophil density was converted to an eosinophil count (eos/h.p.f.) using an h.p.f. size of 0.24 mm 2 , the most commonly reported fi eld size in the literature ( 33 ) .
EoE cases were treated for 8 weeks as clinically indicated with topical corticosteroids (either oval viscous budesonide 1 mg twice daily or fl uticasone from a multi-dose inhaler, 880 mcg twice daily) (34) (35) (36) . At the end of the treatment period, repeat upper endoscopy with biopsy was performed, with collection of a second set of blood and tissue samples as noted above. A second blood sample was also collected for a subset of control subjects at least 2 months aft er baseline samples were collected to assess for stability in biomarkers over time.
Serum data and biomarkers
Before each procedure, a blood sample was obtained from all subjects and centrifuged. Serum was separated, and aliquots were frozen and stored at −80 °C. All samples were labeled with a unique study ID that was blinded as to case/control status, as well as to preor post-treatment status. Aft er patient enrollment and follow-up were complete, samples were removed from the freezer, arranged in a random order, thawed only once, and analyzed in a batch.
Th e serum analytes measured were as follows: IL-4, IL-5, IL-6, IL-9, IL-13, TGF-α , TGF-β , tumor necrosis factor-α , eotaxin-1, -2, and -3, thymic stromal lymphopoietin (TSLP), major basic protein (MBP), and eosinophil-derived neurotoxin (EDN). Th ese were chosen on the basis of prior demonstration of elevated levels in the esophageal tissue and/or in a peripheral source ( 6, 7, (13) (14) (15) (16) (17) (18) (19) (21) (22) (23) (24) (25) (26) (27) (28) (29) (37) (38) (39) (40) . IL-4, IL-5, IL-6, IL-9, IL-13, TGF-α , tumor necrosis factor-α , and eotaxin-1 were measured using an 8-plex panel (cat # HCYTOMAG-60K, Millipore, St Charles, MO). Eotaxin-2, eotaxin-3, and TSLP were measured using a 3-plex panel (cat# HCYP2MAG-62K, Millipore). TGF-β (cat# 559119, BD Biosciences, San Diego, CA, USA) was measured individually via ELISA, as were MBP (cat# ABIN1115874) and EDN (cat# ABIN858221, ABO, Atlanta, GA, USA). Samples were run in duplicate on 96-well plates with standards and positive/ negative controls per manufacturer's instructions. A Bio-Plex 200 system (Bio-Rad Laboratories, Hercules, CA) was used to determine the mean fl uorescence intensity of the multiplex assays. For a subset of EoE cases and non-EoE controls, immunohistochemical staining was used to measure tissue levels of MBP, eotaxin-3, and mast cell tryptase with methodology we have previously described ( 23, 24, 41 ) .
Statistical analysis
Baseline clinical, endoscopic, and histologic characteristics of the cases and controls were described with bivariate analysis using χ 2 for categorical variables and t -tests or Wilcoxon rank-sum for continuous variables as appropriate. Th e mean baseline values of the individual serum biomarkers were compared between cases and controls using a two-sample t -test, whereas baseline and follow-up values for the EoE cases were compared using a paired t -test or a Wilcoxon Signed-rank as appropriate. Additional analyses were performed for the serum values aft er stratifi cation for the following: (i) the presence of atopic diseases (i.e., asthma, atopic dermatitis, allergic rhinitis/sinusitis, and food allergy); and (ii) histologic response to treatment for the EoE cases, defi ned as either <15 eos/h.p.f. or <1 eos/h.p.f. ( 4, 42 ) . Because results were the same with both parametric and nonparametric testing, means and standard deviations are presented in the fi gures. Receiver operating characteristic curves were constructed and areas under the curve were calculated to determine the utility of the serum biomarkers, both individually and collectively, for distinguishing EoE cases from controls at baseline and for monitoring response following treatment. Th e sample size was determined on the basis of the receiver operating characteristic analysis. Enrolling at least 60 cases EoE and 60 controls was expected to provide >80% power to conclude that the area under the curve for an individual marker was signifi cantly greater than 0.50 ( 43 ) .
RESULTS
Patient characteristics
A total of 61 EoE cases and 87 non-EoE controls were included in this study. Compared with controls, EoE cases at diagnosis were more likely to be younger (39 vs. 52 years; P <0.001), male (58% vs. 42%; P =0.05), white (94% vs. 82%), and have an atopic disorder (74% vs. 54%; P =0.01; Table 1 ). Dysphagia was common in both groups but more common in the cases (97% vs. 80%; P =0.002). Heartburn was less common among cases (16% vs. 67%; P <0.001), as was the presence of a hiatal hernia (13 vs. 57%; P <0.001). As expected, the typical endoscopic fi ndings of EoE were also more common in cases ( Table 1 ) . Th e mean of the maximum eosinophil counts in the cases was 146 eos/h.p.f., compared with 3 for the controls ( P <0.001). Aft er treatment of the EoE cases, the mean eosinophil count decreased to 55 eos/h.p.f. ( P <0.001 compared with baseline), with 55% achieving a histologic response of <15 eos/h.p.f. (mean post-treatment eosinophil count of 3 eos/h.p.f.) and 28% achieving normalization of the biopsies (<1 eos/h.p.f.).
Baseline serum biomarkers
At baseline, there were no signifi cant diff erences in any of the biomarkers between cases and controls ( Figure 1 ). For example, mean values of IL-5, IL-13, eotaxin-3, and TSLP for cases and controls were 22±64 vs. 10±47 pg/ml ( P =0.21), 85±160 vs. 43±161 ( P =0.12), 41±159 vs. 21±73 ( P =0.30), and 15±33 vs. 19±109 ( P =0.77). Median values for the same comparisons did not change the results. Receiver operating characteristic analysis confi rmed that there was little diagnostic utility for the biomarkers either individually (areas under the curve ranging from 0.40 to 0.68) or in sum (area under the curve=0.69). Th ere were also no diff erences between cases and controls aft er stratifi cation by atopic status (data not shown). Of note, tissue levels of MBP, eotaxin-3, and mast cell tryptase were markedly elevated in esophageal biopsies from a subset of cases as compared with controls ( Supplementary  Table online) .
Post-treatment serum biomarkers
A total of 51 EoE cases had paired pre-and post-treatment serum available for analysis. Th ere were no signifi cant diff erences detected overall before and aft er treatment ( Figure 2a ). For example, values of IL-5, IL-13, eotaxin-3, and TSLP pre-and post-treatment were 19±57 vs. 17±56 pg/ml ( P =0.81), 71±152 vs. 43±95 ( P =0.18), 42±174 vs. 28±76 ( P =0.41), and 14±33 vs. 18±40 ( P =0.29). Median values for the same comparisons did not change the results. Th ere were also no diff erences detected aft er stratification by treatment responder status, either at the <15 eos/h.p.f. level ( Figure 2b ) or at the <1 eos/h.p.f. level (data not shown). Th ere were 17 controls with follow-up specimens, and there were no diff erences in any of the serum biomarker levels over time in this group ( Supplementary Figure ) .
DISCUSSION
Given the serial upper endoscopies required for diagnosis and monitoring of EoE, current clinical practice is cumbersome for patients, invasive, and expensive. Noninvasive methods for diagnosis and monitoring would be extremely valuable in this condition, and a serum test for a biomarker panel would be ideal. In this prospective study that collected clinical, endoscopic, histologic, and biologic data on incident cases of EoE and non-EoE controls, we investigated the utility of a large number of the most promising serum biomarkers for both diagnosis and monitoring of EoE. Despite choosing markers shown in multiple studies to be increased in esophageal tissue in EoE, we were unable to demonstrate any diff erence in the serum measures between cases and controls or did we fi nd any that were responsive to treatment. Th ese results were unaff ected by atopy status of the cases and controls or by the level of treatment response measured histologically. Previous studies have identifi ed multiple biomarkers that are characteristic of EoE at the esophageal tissue level. Th ese include Th 2-related cytokines, most notably IL-5 and IL-13, chemokines, such as eotaxin-3, eosinophil granule proteins, microRNAs, and mast cells (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (25) (26) (27) (28) (29) 37, 38, 41, (44) (45) (46) (47) (48) (49) . However, data on serum biomarkers are sparse and confl icting and primarily come from either small studies examining mechanisms of EoE or sub-analyses of clinical trials focusing on a few cytokines, chemokines, or granule proteins. Th e preponderance of the data are also in children.
Konikoff and colleagues studied 47 children, 16 of whom had active EoE, and assessed a number of plasma biomarkers, including IL-5, eotaxin-1, -2, and -3, and EDN ( 19 ) . Th ey found that plasma EDN and eotaxin-3 correlated with tissue eosinophil levels and were also signifi cantly increased in active EoE compared with controls, although the diff erences were mild (50.3 vs. 31.1 ng/ ml for EDN and 37.7 vs. 11.5 pg/ml for eotaxin-3). Notably, they did not report diff erences in IL-5, eotaxin-1, or -2. Changes in eotaxin-1 and -3 were also not observed following treatment with an anti-IL-13 antibody in a recent trial ( 50 ) . In contrast, a mechanistic study of the role of fi broblast growth factor by Huang and colleagues showed elevated levels of plasma IL-5 and IL-13 in 35 pediatric EoE cases compared with 8 healthy controls ( 51 ) . IL-5 was also noted to be elevated in EoE compared with controls in a study of eosinophil function in 12 adults with EoE ( 40 ). Subbarao and colleagues studied serum IL-5 and EDN in 60 children with EoE and 20 controls and found that although EDN levels were signifi cantly higher in cases compared with controls (23.5 vs. 2.7 ng/ ml), IL-5 levels were not ( 18 ) . Th ey also found that serum EDN levels signifi cantly decreased aft er treatment. Of studies that have examined serum eosinophil cationic protein (ECP) aft er treatment for EoE, two studies showed that ECP decreased aft er treatment ( 52,53, ) whereas one found no change. ( 54 ) We are unaware of any prior published studies examining serum MBP in EoE. Our study does not confi rm the previous fi ndings related to EDN or IL-5 and suggests that none of the panel of cytokines, chemokines, and eosinophil granules that we examined has utility as a biomarker panel. EGD, esophagogastroduodenoscopy; EoE, eosinophilic esophagitis; eos/h.p.f., eosinophils per high-power fi eld; IQR, interquartile range. a n =60 EoE cases with follow-up biopsy data.
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with PPI-responsive esophageal eosinophilia. Although it has been recently reported that PPIs have anti-infl ammatory and antieosinophilic eff ects independent of their anti-acid eff ect ( 55, 56 ) , because the EoE cases in the present study all had a high tissue level of eosinophilic infl ammation despite PPI use, it is not likely that PPIs impacted serum biomarker levels, but we are not able to test this directly with our study design. Given the lack of signal in the serum for our biomarker panel, it may be that the brisk esophageal infl ammation is not refl ected systemically. Although we did not measure the levels of the serum biomarkers in the esophageal biopsy specimens of the subjects included in this study either at baseline or aft er steroid treatment, we feel that it would be unlikely for baseline tissue levels to be low in these patients. For example, the EoE cases were highly infl amed, with an average peak esophageal eosinophil count of 146/h.p.f., and a subset of the EoE subjects who did have staining for MBP, eotaxin-3, and mast cell tryptase had markedly elevated tissue levels compared with controls. Minimally invasive diagnostic techniques are under development to sample the esophagus ( 57, 58 ) , and these might be more amenable to a biomarker panel.
Our study also has a number of strengths. It was a prospective study specifi cally designed to evaluate biomarkers in a population of well-characterized incident EoE cases and non-EoE controls. Th e omission of prevalent cases makes it impossible that previous medical or dietary therapy for EoE would account for any observed diff erences between cases and controls. It is the largest study to date focusing on biomarkers for diagnosis and monitoring of EoE, and the only one of its kind to be done in an adult population. Uniform methods were used for case-control identifi cation, sample handling, and analysis, and all baseline samples were obtained before the EoE diagnosis was known. Follow-up samples were obtained with identical methods as at baseline, and outcomes (eosinophil counts; biomarker levels) were quantifi ed in a blinded manner, using rigorous, previously validated methods. Th ese methodologic strengths make the data reliable and valid.
In conclusion, in this large prospective study, a panel of infl ammatory markers associated with EoE pathogenesis and known to be elevated in esophageal tissue of patients with EoE were not increased in the serum of EoE patients at baseline compared with non-EoE controls. Th ese markers also were unresponsive to treatment, even in the face of marked decrements in the esophageal eosinophil count. Th erefore, none of these biomarkers are likely candidates for a serum test. Instead, focus should move to novel blood-based biomarkers for diagnosing and monitoring EoE, as well as the development of more economical, non-endoscopic methods of sampling the esophageal mucosa. When interpreting the data from this study, there are potential limitations to consider. Because the results were not positive, there is the possibility of a type II error. However, this is the largest study to date assessing biomarkers for diagnosis and monitoring of EoE, and it was powered to detect clinical meaningful diff erences based on receiver operating characteristic curve analysis. It is possible that diff erent power calculation methods could have increased the sample size required, but given the lack of suggestive trends in our data, if any statistically signifi cant diff erences between the assays could be detected with larger numbers of subjects, the clinical utility of such diff erences would be doubtful. Diff erences in specimen handling or degradation over time are unlikely to have contributed to our results, and analysis of a subset of controls with samples over time showed stability in the biomarker measures. All samples were handled identically, remained frozen until analysis, and were there to be degradation it would likely be non-diff erential for both the case and control groups. Finally, we did not include a PPIresponsive esophageal eosinophilia group in the study, as the main goals were to develop biomarkers to detect EoE and monitor the response of EoE to treatment over time, not to distinguish EoE from PPI-responsive esophageal eosinophilia. Th erefore, we cannot comment on the utility of these serum biomarkers in patients , and non-responders at the ≥15 eos/h.p.f. level (gray bars). For both panels, the top of the bars represents the mean biomarker values, the error bars represent the standard deviation, the y axis is on a log scale, and all concentrations are in pg/ml with the exception of major basic protein (MBP), which is in ng/ml. *Concentration of MPB is ng/ml.
